Citigroup Inc. Increases Holdings in Abeona Therapeutics Inc (NASDAQ:ABEO)

Citigroup Inc. lifted its position in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 10.1% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 616,668 shares of the biopharmaceutical company’s stock after purchasing an additional 56,332 shares during the quarter. Citigroup Inc.’s holdings in Abeona Therapeutics were worth $3,897,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. purchased a new position in shares of Abeona Therapeutics during the 3rd quarter valued at about $151,000. GSA Capital Partners LLP raised its holdings in shares of Abeona Therapeutics by 54.3% during the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after buying an additional 33,831 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Abeona Therapeutics by 2.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock valued at $515,000 after buying an additional 2,434 shares in the last quarter. abrdn plc raised its holdings in shares of Abeona Therapeutics by 158.8% during the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after buying an additional 200,647 shares in the last quarter. Finally, Simplify Asset Management Inc. purchased a new position in shares of Abeona Therapeutics during the 2nd quarter valued at about $1,732,000. 80.56% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ABEO. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a report on Monday, November 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. Finally, StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 28th.

Abeona Therapeutics Stock Down 3.6 %

Shares of Abeona Therapeutics stock opened at $6.11 on Wednesday. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The business’s 50 day simple moving average is $6.27 and its two-hundred day simple moving average is $5.37. Abeona Therapeutics Inc has a one year low of $3.05 and a one year high of $9.01.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.